Medical Marijuana, Inc. subsidiary HempMeds® Brasil recently completed a three date educational tour of Southern Brazil.
Earlier this month, HempMeds® Brasil successfully hosted a trio of cannabis symposiums in the Rio Grande do Sul region of Brazil from March 19-23 and was held in the cities of Canoas, Passo Fundo, and Porto Alegre.
The event was put on in conjunction with the National Association of Users of Cannabidiol (ANUC), an organization in Brazil made up of patients and their families with the mission of supporting those in Brazil in need of CBD, including legal guidelines, assistance finding doctors, and even financial support.
The goal behind these events was to share scientific information about CBD with practicing doctors, to strengthen ties with the medical community in Brazil, and to disperse an understanding of the benefits of CBD to Brazil’s population through the country’s medical community. The three day educational tour stopped at hospitals and universities in the region to share this critical information with the medical communities in Brazil.
News of the successful events and the planned study was found in international media outlets, including the following:
Experts and CBD pioneers from Brazil’s medical community spoke at the three events, including Junior Gibelli, Director of Medical Affairs at HempMeds® Brasil; pediatric neurologist Dr. Luiz Fernando Fonseca; Dr. Alan Fröhlich, neurologist of the Service of Neurology and Neurosurgery; Dr. Daniel Lima Varela, Professor of Neurology at IMED and Coordinator at the Outpatient Clinic Hospital in São Vicente de Paulo; and Dr. Pablo Winckler, neurologist and specialist in diabetic neuropathy.
Dr. Stuart Titus, CEO of Medical Marijuana, Inc., also spoke at each of these events as a representative for the Medical Marijuana, Inc. family of companies. He shared his experience and extensive knowledge about the physiological role and benefits of CBD and discussed upcoming potential research opportunities in Brazil and the importance of clinical research in order to better understand CBD’s potential.
During the tour, the Lutheran University of Brazil announced that it has taken steps to begin research to evaluate the use of CBD in patients with Parkinson’s disease. The announcement was made during the event on Monday evening, March 19th, at the Lutheran University of Brazil in Canoas.
The research will be completed in partnership with Dr. Kelson James Almeida, noted neurologist and current technical director of the university’s Integrated Rehabilitation Center. The clinical study is currently awaiting approval by the university’s college ethics committee.
If approved, the study will involve 120 patients with Parkinson’s disease in several Brazilian states. The ultimate goal of the research is to examine whether CBD would have the ability to reduce effects such as tremors and stiffness in the muscles of those suffering from the disease.
Medical Marijuana, Inc. has agreed to provide the CBD for the research project as part of its efforts to support access to CBD in Brazil and around the world.
Who is HempMeds® Brasil?
HempMeds® Brasil was the first company to receive approval from the Anvisa, the health authority in Brazil, to import a product based on hemp-derived CBD.
Currently, HempMeds® Brasil is authorized to supply its products to patients with import authorization and a prescription for CBD. For some indications, our CBD products can be subsidized by the Brazilian government; HempMeds® Brasil continues to work on gaining approvals for other additional indications.
You can learn more about developments from HempMeds® Brasil and the rest of the Medical Marijuana, Inc. portfolio of companies on our news feed.